Eris Lifesciences, a company in the Pharmaceuticals industry, reported revenue of ₹892 crore and net profit of ₹187 crore for the September 2026 quarter.
Eris Lifesciences (NSE: ERIS) closed at ₹1,317.20 on 20 Nov 2026, down 21.1% over the past year. Its market capitalisation is ₹18,275 crore and it trades at 24.5 times earnings.
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.